Product Details
Kerendia
Finerenone10 mg
Tablet
DIN/PIN/NPN
02531917
Manufacturer
Bayer Inc., Health Care Division
Formulary Listing Date
2024-03-28
Unit Price
3.2565
Amount MOH Pays
3.2565
Coverage Status
Limited Use Product
ODB Formulary Therapeutic Classification
Therapeutic Note
NO
ATC Code
C03DA05
Interchangeable Products
NOLU Clinical Criteria
LU Code | Auth. Period | Clinical Criteria |
---|---|---|
700 | 1 year | For use as an adjunct to standard-of-care (SOC) therapy in adult patients diagnosed with BOTH chronic kidney disease (CKD) and type 2 diabetes (T2D) to reduce the risk of end-stage kidney disease and a sustained decrease in estimated glomerular filtration rate (eGFR), and cardiovascular death, nonfatal myocardial infarction, and hospitalization for heart failure in patients who meet the following criteria:
Discontinuation Criteria: Patients meeting the initiation criteria and started on finerenone should be discontinued on treatment if the patient's eGFR is less than 15mL/min/1.73 square metres and/or if the urinary albumin-to-creatinine ratio (UACR) has increased from baseline level after starting treatment with finerenone. Approved Dosage: - 20mg once daily for patients with an eGFR of at least 60mL/min/1.73 square metres OR - 10mg once daily for patients with an eGFR of at least 25mL/min/1.73 square metres to less than 60mL/min/1.73 square metres |